Our Partners

Denmark’s healthcare system is highly standardized, integrated, and well-positioned for innovation. AIDA operates within this dynamic environment, strengthened by close collaboration with key clinical and research partners such as Rigshospitalet, the Danish Breast Cancer Group (DBCG), and international organizations like Genomic Medicine Belgium.

AIDA has also benefited from the support of leading Danish and European institutions, including the BioInnovation Institute (BII), founded by the Novo Nordisk Foundation, the Export and Investment Fund of Denmark (EIFO), ff4EuroHPC, and Health Care Hub Copenhagen (HTHC). Their backing has been instrumental in helping AIDA develop its first product and advance its mission to improve patient outcomes through personalized treatment.

GMS logo with stylized circuit lines and dots.
Logo for EuroHPC with a stylized 'ff' and a hexagonal outline on a dark blue background.
Close-up of the letters 'BII' in bold, dark green font.
Logo for Danish Breast Cancer Group with stylized blue and gray text
Text in blue says 'novo nordisk fonden' vertically aligned.
Black crown icon with the word 'ELIFO' underneath, all in black on a white background.

Building on this momentum.

We are looking for collaborators.

We are actively seeking collaboration with clinical oncology groups dedicated to improving patient treatment. We want partners with expertise in healthcare and life sciences, strong clinical and regulatory networks, and experience with RNA expression analysis technologies. Regulatory experts are also essential to help navigate approval processes. Our goal is to scale innovative solutions that truly benefit patients